Proclarix’ performance in ruling out patients with no or indolent prostate cancer: evaluation in a Danish population
Ralph Schiess, Alcibiade Athanasiou, Madlen M.E. Kasten, Torben F Hansen, Gitte E Kissow, Louise F Obro, Jonna S Madsen, Mads H Poulsen, Palle J Osther, Ahmed H. Zedan
Springer Nature ·
2026-05-09
· DOI 10.1186/s12885-026-16118-8
The publisher did not provide an abstract — full text is available via the link below.
Ralph Schiess, Alcibiade Athanasiou, Madlen M.E. Kasten, Torben F Hansen, Gitte E Kissow, Louise F Obro et al. Proclarix’ performance in ruling out patients with no or indolent prostate cancer: evaluation in a Danish population. // BMC Cancer. – 2026. – DOI: 10.1186/s12885-026-16118-8. – URL: https://doi.org/10.1186/s12885-026-16118-8
Ralph Schiess, Alcibiade Athanasiou, Madlen M.E. Kasten, Torben F Hansen, Gitte E Kissow, Louise F Obro, Jonna S Madsen, Mads H Poulsen, Palle J Osther, & Ahmed H. Zedan (2026). Proclarix’ performance in ruling out patients with no or indolent prostate cancer: evaluation in a Danish population. BMC Cancer. https://doi.org/10.1186/s12885-026-16118-8
Ralph Schiess, et al. “Proclarix’ performance in ruling out patients with no or indolent prostate cancer: evaluation in a Danish population.” BMC Cancer, 2026. doi:10.1186/s12885-026-16118-8.
@article{Schiess2026,
title = {Proclarix’ performance in ruling out patients with no or indolent prostate cancer: evaluation in a Danish population},
author = {Schiess, Ralph and Athanasiou, Alcibiade and Kasten, Madlen M.E. and Hansen, Torben F and Kissow, Gitte E and Obro, Louise F and Madsen, Jonna S and Poulsen, Mads H and Osther, Palle J and Zedan, Ahmed H.},
journal = {BMC Cancer},
year = {2026},
doi = {10.1186/s12885-026-16118-8},
url = {https://doi.org/10.1186/s12885-026-16118-8}
}